Abstract：
BACKGROUND: Chemotherapy is an integral part of cancer management which is associated with phlebitis in around 70% of patients receiving intravenous chemotherapy infusion. Thus, we aimed to estimate the incidence, severity, and management of phlebitis associated with chemotherapy infusion among cancer patients.
METHODS: A prospective study was conducted among 145 patients receiving intravenous chemotherapy for the duration of six months in the oncology department. The relevant data for phlebitis was obtained and assessed using Phlebitis Grading Scale and Visual Analogue Scale for the assessment of severity and pain due to phlebitis, respectively.
RESULTS: Out of 145 patients, female (56.6%) patients predominated over male patients (43.5%) with a mean age of 53.5 ± 11.82 years. Phlebitis was encountered in 30.34% of patients among whom 22.8% (33) were females followed by 7.6% were males and the majority of patients (13.1%) were from the 46 to 60 years age group. Phlebitis was observed frequently among stage 2 (11%) and satge 4 (11%) patients. The highest incidence of phlebitis was seen among hypertensive (34.09%) and diabetic patients (27.27%) followed by those receiving chemotherapy through the 20-gauge intravenous cannula (22.8%) and 22-gauge (6.9%). Platinum compounds (56.8%) were commonly associated with phlebitis, followed by cyclophosphamide (20.5%). Heparin and benzyl nicotinate topical gel were used to treat phlebitis.
CONCLUSIONS: Platinum and cyclophosphamide are commonly associated with phlebitis which can be managed by topical heparin plus benzyl nicotinate. Phlebitis shouldn\'t be ignored as it has a high incidence, affects the quality of life, and increases the treatment burden.
METHODS: A prospective study was conducted among 145 patients receiving intravenous chemotherapy for the duration of six months in the oncology department. The relevant data for phlebitis was obtained and assessed using Phlebitis Grading Scale and Visual Analogue Scale for the assessment of severity and pain due to phlebitis, respectively.
RESULTS: Out of 145 patients, female (56.6%) patients predominated over male patients (43.5%) with a mean age of 53.5 ± 11.82 years. Phlebitis was encountered in 30.34% of patients among whom 22.8% (33) were females followed by 7.6% were males and the majority of patients (13.1%) were from the 46 to 60 years age group. Phlebitis was observed frequently among stage 2 (11%) and satge 4 (11%) patients. The highest incidence of phlebitis was seen among hypertensive (34.09%) and diabetic patients (27.27%) followed by those receiving chemotherapy through the 20-gauge intravenous cannula (22.8%) and 22-gauge (6.9%). Platinum compounds (56.8%) were commonly associated with phlebitis, followed by cyclophosphamide (20.5%). Heparin and benzyl nicotinate topical gel were used to treat phlebitis.
CONCLUSIONS: Platinum and cyclophosphamide are commonly associated with phlebitis which can be managed by topical heparin plus benzyl nicotinate. Phlebitis shouldn\'t be ignored as it has a high incidence, affects the quality of life, and increases the treatment burden.
摘要：
背景：化疗是癌症治疗不可或缺的一部分，在接受静脉化疗的患者中约70%与静脉炎相关。因此，我们的目的是估计发病率，严重程度,以及癌症患者化疗输液相关静脉炎的管理。
方法：在肿瘤科接受为期6个月的静脉化疗的145名患者中进行了一项前瞻性研究。获得静脉炎的相关数据，并使用静脉炎分级量表和视觉模拟量表评估静脉炎的严重程度和疼痛，分别。
结果：在145名患者中，女性患者(56.6%)多于男性患者(43.5%),平均年龄为53.5±11.82岁.在30.34％的患者中遇到静脉炎，其中22.8％（33）是女性，其次是7.6％是男性，大多数患者（13.1％）来自46至60岁年龄段。在第2阶段（11％）和第4阶段（11％）的患者中经常观察到静脉炎。静脉炎的发生率最高的是高血压患者（34.09％）和糖尿病患者（27.27％），其次是通过20号静脉插管（22.8％）和22号静脉插管（6.9％）接受化疗的患者。铂类化合物（56.8%）通常与静脉炎有关，其次是环磷酰胺（20.5%）。肝素和烟酸苄酯局部凝胶用于治疗静脉炎。
结论：铂和环磷酰胺通常与静脉炎相关，可通过局部肝素加烟酸苄酯治疗。静脉炎的发病率很高，不容忽视，影响生活质量，增加了治疗负担。
方法：在肿瘤科接受为期6个月的静脉化疗的145名患者中进行了一项前瞻性研究。获得静脉炎的相关数据，并使用静脉炎分级量表和视觉模拟量表评估静脉炎的严重程度和疼痛，分别。
结果：在145名患者中，女性患者(56.6%)多于男性患者(43.5%),平均年龄为53.5±11.82岁.在30.34％的患者中遇到静脉炎，其中22.8％（33）是女性，其次是7.6％是男性，大多数患者（13.1％）来自46至60岁年龄段。在第2阶段（11％）和第4阶段（11％）的患者中经常观察到静脉炎。静脉炎的发生率最高的是高血压患者（34.09％）和糖尿病患者（27.27％），其次是通过20号静脉插管（22.8％）和22号静脉插管（6.9％）接受化疗的患者。铂类化合物（56.8%）通常与静脉炎有关，其次是环磷酰胺（20.5%）。肝素和烟酸苄酯局部凝胶用于治疗静脉炎。
结论：铂和环磷酰胺通常与静脉炎相关，可通过局部肝素加烟酸苄酯治疗。静脉炎的发病率很高，不容忽视，影响生活质量，增加了治疗负担。
